Curing age
related diseases
Ten drug assets, more than 100 international patents, and an AI engine that predicts clinical outcomes with better than 80% accuracy.
Inversagen AI was formed in 2025 to combine two proven bodies of work: BioAtla's patented antibody technology and GATC Health's predictive AI. Together they give us ten drug assets, a Phase 3 oncology programme, and a pipeline aimed at the biology of aging itself.
Drug development is still the most expensive guess in the economy.
Risky
Roughly 92% of new drugs fail somewhere between discovery and approval. Every failure is paid for by patients who waited and investors who funded the attempt.
Costly
The average R&D bill behind a single FDA approval now runs past $1 billion, most of it spent on programmes that never reach a label.
Slow
Ten to twelve years is the standard road from first molecule to launch. Age-related disease does not wait that long.
Proven science, predicted outcomes
Two companies spent more than five years and $165 million building the halves of this business. Inversagen puts them in one place: antibodies that can tell good biology from bad, and a model that tells us which trial to run before we run it.
Predictive drug intelligence
GATC Health's engine ranks biomarkers, identifies targets, and models on and off target effects, ADME, and toxicology. Independent study puts predicted outcomes above 80% accuracy.
Conditionally Active Biologics
BioAtla's CAB and CIAO antibody platforms activate only in diseased tissue. That selectivity is what lets us clear harmful senescent cells and leave the useful ones alone.
Ten assets, 100+ patents
A portfolio spanning oncology, immune disease, CNS, and age-related conditions of the bone, kidney, heart, liver, and lung.
Clinical stage today
Oz-V, our ROR2 asset, is in Phase 3 for OPSCC. Two anti-aging programmes follow it into IND-enabling work through 2027.
Four steps from molecule to market
Select
Rank targets and candidates against biological, clinical, and molecular data before a dollar of trial spend is committed. Weak programmes get stopped early.
Design
Model patient populations, endpoints, and protocols in silico. Trials run smaller, enrol faster, and answer the question they were built to answer.
Execute
Run studies inside the double-blind frameworks the FDA and EMA already trust, with senior pharma operators from BioAtla and GATC Health on the ground.
Realize
License, partner, or sell. Ernst & Young values each asset at $50 million to $150 million today, with commercial potential above $1 billion.
Frequently asked questions
How can a model predict trial outcomes?+
GATC Health trained its engine on biological, clinical, and molecular data across two decades of drug programmes. An independent study put predicted outcomes above 80% accuracy against an industry failure rate near 92%. We use it to choose and design trials, then run those trials inside the same double-blind frameworks regulators already trust.
Why target senescence rather than one disease?+
Senescent cells drive most of what we call aging. Some of them are useful, protecting tissue and suppressing tumours. Our antibody technology is unusual in being able to tell the two apart, which is what makes clearing the harmful ones viable.
What validates the pipeline value?+
Ernst & Young analysed both the assets and the predictive platform and put each asset at $50 million to $150 million today, with commercial potential above $1 billion. Lloyd's of London has agreed to insure clinical trials on the strength of the same risk analysis.
Who is behind the company?+
Inversagen AI was formed in 2025 by GATC Health, a tech-bio company focused on predictive drug development and Inversagen LLC, a spin out of BioAtla, a San Diego public biotech with more than 700 issued patents and applications. The founders have put more than $165 million into the underlying IP.